Poly-L-lysine-coated nanoparticles: a potent delivery system to enhance DNA vaccine efficacy (Q40217887)

18 September 2017

title

Poly-L-lysine-coated nanoparticles: a potent delivery system to enhance DNA vaccine efficacy (English)

1 reference

18 September 2017

0 references

Anja Scholzen

0 references

Vasso Apostolopoulos

0 references

Magdalena Plebanski

1 reference

18 September 2017

Gabriela Minigo

1 reference

18 September 2017

Choon K Tang

1 reference

18 September 2017

Jennifer C Hanley

1 reference

18 September 2017

Martha Kalkanidis

1 reference

18 September 2017

Geoffrey A Pietersz

1 reference

18 September 2017

language of work or name

English

0 references

publication date

10 October 2006

1 reference

18 September 2017

1 reference

inferred from page(s)

published in

Vaccine

1 reference

18 September 2017

1 reference

18 September 2017

1 reference

18 September 2017

page(s)

1316-1327

1 reference

DNA vaccines: immunology, application, and optimization*

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

The immunologist’s grail: Vaccines that generate cellular immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Heterologous protection against influenza by injection of DNA encoding a viral protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Gene inoculation generates immune responses against human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Preclinical efficacy of a prototype DNA vaccine: Enhanced protection against antigenic drift in influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Microparticles for the delivery of DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Chitosan-based nanoparticles for topical genetic immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Cationic microparticles: A potent delivery system for DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Caveolae: stable membrane domains with a potential for internalization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Cross-presentation, dendritic cells, tolerance and immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Phagosomes are competent organelles for antigen cross-presentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Clathrin-dependent or not: is it still the question?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Mechanisms of phagocytosis in macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Cross-presentation: underlying mechanisms and role in immune surveillance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Vaccines that facilitate antigen entry into dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

A central role for tissue-resident dendritic cells in innate responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Origin, maturation and antigen presenting function of dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Mechanisms of antigen uptake for presentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Pathogen recognition and development of particulate vaccines: does size matter?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

40 nm, but not 750 or 1,500 nm, nanoparticles enter epidermal CD1a+ cells after transcutaneous application on human skin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Introduction of soluble protein into the class I pathway of antigen processing and presentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Gene transfer in vivo: sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Factors affecting blood clearance and in vivo distribution of polyelectrolyte complexes for gene delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Exact prediction of a natural T cell epitope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

DO11.10 and OT-II T cells recognize a C-terminal ovalbumin 323-339 epitope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Antigen epitope-expressing cytokines for DNA immunization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Characterization and biological evaluation of a microparticle adjuvant formulation for plasmid DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Pulmonary delivery of respiratory syncytial virus DNA vaccines using macroaggregated albumin particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

A cationic sub-micron emulsion (MF59/DOTAP) is an effective delivery system for DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Direct gene transfer into mouse muscle in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

The immunobiology of muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Dendritic cells and the control of immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Cytosolic soluble proteins induce DNA release from DNA--gene carrier complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Danger signals: SOS to the immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Dendritic cells: immune regulators in health and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

High-avidity antitumor T-cell generation by toll receptor 8-primed, myeloid- derived dendritic cells is mediated by IL-12 production.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Non-methylated CpG motif packaged into fusogenic liposomes enhance antigen-specific immunity in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Th2 activities induced during virgin T cell priming in the absence of IL-4, IL-13, and B cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

Systemic immune responses in sheep, induced by a novel nano-bead adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.086

10.1016/J.VACCINE.2006.09.086

7 January 2021

Identifiers

DOI

1 reference

18 September 2017

1 reference